Introduction
Although psychomotor stimulants, such as amphetamine and cocaine, increase brain concentrations of both dopamine and norepinephrine, studies utilizing systemic administration of dopaminergic and noradrenergic antagonists originally established a dominant role for dopamine in stimulant self-administration [1] [2] [3] [4] . Recent findings, however, suggest that regionally specific noradrenergic neurotransmission within the medial prefrontal cortex and ventral tegmental area is in a position to influence stimulant reward by modulating dopamine in the nucleus accumbens, an area critical for mediating both natural and drug rewards. For example, noradrenergic lesions of the medial prefrontal cortex prevent conditioned place preference for cocaine [5] and amphetamine [6] . This blunted preference may be due to impaired signaling at a1 receptors because blockade of these receptors in the medial prefrontal cortex reduces cocaine-induced [5] and amphetamine-induced [7] elevations in nucleus accumbens dopamine as well as amphetamine-induced hyperlocomotion [7, 8] . Furthermore, preference for cocaine, cocaine-induced and amphetamine-induced hyperlocomotion, and amphetamine-induced elevations in nucleus accumbens dopamine are all blunted in mice lacking a1b receptors [9, 10] . Regarding noradrenergic functioning in the ventral tegmental area, amphetamine-induced burst firing of dopamine neurons in this brain region is dependent on activation of local a1 noradrenergic, but not a2 noradrenergic or dopaminergic, receptors [11] . Taken together, a1 receptor-mediated neurotransmission in the medial prefrontal cortex and ventral tegmental area may contribute to the rewarding properties of psychomotor stimulants to maintain self-administration behavior.
We have thus examined whether local administration of the a1 receptor antagonist terazosin into either the medial prefrontal cortex or ventral tegmental area alters cocaine self-administration in well-trained rats. As a positive control, we also tested the D1 dopamine antagonist SCH23390, which is known to increase cocaine self-administration when microinjected into the medial prefrontal cortex [12] or ventral tegmental area [13] . all procedures were approved by the local Animal Care and Use Committee. Rats were individually housed under a reverse light-dark cycle and were tested during the dark phase.
Surgery
Rats were surgically implanted with bilateral guide cannulae (Plastics One, Roanoke, Virginia, USA) into either the medial prefrontal cortex or ventral tegmental area and an intravenous catheter made of Micro-Renathane tubing (Braintree Scientific, Braintree, Massachusetts, USA) into the right external jugular vein. Guide cannulae were inserted at an angle toward the midline for the medial prefrontal cortex (131; A/P = + 3.0 mm, M/L = ± 0.7 mm, D/V = -3.6 mm) and ventral tegmental area (161; A/P = -5.7 mm, M/L = ± 0.5 mm, D/V = -8.4 mm) and were positioned 1.0 mm above the injection site. The intravenous catheters were flushed daily with 0.3 ml of saline with gentamicin (4 mg/ml) and heparin (30 U/ml). Six rats were excluded from the experiment because their catheters developed leaks.
Experimental design
The current study consisted of two experimental phases: cocaine self-administration training (10-14 days) and cocaine self-administration testing with intracranial microinjection (1 day). Rats were randomly assigned to one of 10 groups defined by the brain region targeted (medial prefrontal cortex or ventral tegmental area) and the drug type used [saline, terazosin (1.0, 5.0, or 10 mM), or SCH23390 (12.3 mM)] for intracranial microinjection before cocaine self-administration testing.
Cocaine self-administration training
After recovery from surgery (3-5 days), rats were trained to self-administer cocaine in daily 4-h sessions. Ten operant chambers (Med Associates, Georgia, Vermont, USA), each measuring 25 Â 27 Â 30 cm and equipped with two levers, were used for all self-administration procedures. Reinforced lever presses on a retractable 'active lever' delivered an infusion of cocaine (1.0 mg/kg/ infusion, intravenously). This dose of cocaine is on the descending limb of the dose-response curve [14] and has been verified to be sensitive to intra-ventral tegmental area administration of SCH23390 [13] -one of the designated positive controls in the current study. A reinforced lever press on the active lever also caused a stimulus light above the lever to turn on for 20 s, during which further active lever presses were recorded but did not lead to additional infusions. Presses on a stationary 'inactive lever' were counted but had no scheduled consequence. Rats were trained for at least 10 days and were required to satisfy predetermined training criteria within 14 days. The training criteria were two consecutive days of no less than 20 infusions and no more than five presses on the inactive lever during the 4-h session. Four rats failed to satisfy these criteria and were excluded.
Cocaine self-administration testing with intracranial microinjection
The day after the last training session, each animal received bilateral microinjections (0.5 ml/side) of terazosin, SCH23390, or saline into either the medial prefrontal cortex or ventral tegmental area immediately before a normal cocaine self-administration session. Terazosin hydrochloride and R( + )-SCH23390 hydrochloride were purchased from Sigma-Aldrich (St Louis, Missouri, USA). Terazosin was used instead of more than the commonly used a1 antagonist, prazosin, because of its higher solubility in isotonic saline. Three doses of terazosin (1.0, 5.0, and 10 mM) and one dose of SCH23390 (12.3 mM) were tested. The doses of terazosin were determined on the basis of the findings by Darracq et al. [7] . In this study, bilateral microinjection of prazosin into the medial prefrontal cortex at 1.0 mM reduced amphetamine-induced elevations in locomotor activity as well as extracellular dopamine in the nucleus accumbens. The receptor binding affinity of terazosin for a1 receptors is approximately 10-fold lower than that of prazosin [15] , thus 10 mM of terazosin was chosen as the highest dose. The dose of SCH23390 was based on two previous findings: bilateral microinjections of SCH23390 at 12.3 mM into the medial prefrontal cortex [12] or ventral tegmental area [13] increased the rate of cocaine self-administration. The total number of infusions and active and inactive lever presses were recorded and used for statistical analysis.
Cannula placement verification
Upon completion of all experimental procedures, rats were euthanized with pentobarbital [30 mg/kg, intraperitoneally (i.p.)] supplemented with chloral hydrate (140 mg/kg, i.p.). The brains were removed, postfixed in 10% formalin, and sliced into coronal sections (40 mm). The sections were then stained on gelatin-coated slides with cresyl violet for verification of cannula placements. Only data obtained from animals with both cannula tips placed within the medial prefrontal cortex or ventral tegmental area were retained for statistical analysis ( Fig. 1a and b ) [16] . Eight animals were excluded because one or two of the bilateral cannulae were located outside these brain regions. Figure 1a (medial prefrontal cortex) and Fig. 1b (ventral tegmental area) depict representative cannula placements.
Statistical analysis
The data collected from the medial prefrontal cortex and ventral tegmental area groups were analyzed separately. The total number of cocaine infusions, active lever presses, and inactive lever presses were recorded and separately analyzed using a one-way analysis of variance (ANOVA) with the type of microinjection (five levels) as the between-subjects factor. In addition, to assess the effects of terazosin on the pattern of cocaine-seeking behavior throughout the test session, the cumulative number of active lever presses was divided into 10-min bins, which were analyzed using a two-way repeated measures ANOVA with the type of microinjection [five levels: saline, terazosin (1.0, 5.0, or 10mM), or SCH23390 (12.3 mM)] as the between-subjects factor and time (24 levels) as the withinsubjects factor. Post-hoc Fisher's least significant difference test (LSD) comparisons were made when appropriate following ANOVA. All analyses were conducted with Statistica (1999 edition) statistical software (StatSoft, Tulsa, Oklahoma, USA).
Results
The bilateral microinjection of terazosin into the medial prefrontal cortex failed to affect cocaine self-administration at all doses tested, whereas that of SCH23390 significantly increased cocaine intake and cocaine-seeking behavior ( Fig. 2a and b) . The ANOVA conducted on the total number of cocaine infusions obtained revealed a significant effect of microinjection [F(4,26) = 18.16; P < 0.01]. The ANOVA conducted on the cumulative number of active lever presses per 10-min bin revealed a significant effect of time [F(23,598) = 127.03; P < 0.001] and a significant microinjection Â time interaction [F(92,598) = 2.61; P < 0.001]. Post-hoc LSD comparisons revealed that only rats receiving intra-medial prefrontal cortex SCH23390 obtained significantly more cocaine infusions (P < 0.05) and made significantly more active lever presses than did the saline-treated animals (P < 0.01). The ANOVA conducted on the total number of inactive lever presses revealed no significant effect. Four rats with guide cannula tips located outside the medial prefrontal cortex showed no change in cocaine self-administration following microinjection of terazosin (data not shown).
The bilateral microinjection of terazosin into the ventral tegmental area also failed to affect cocaine self-administration at all doses tested, whereas that of SCH23390 significantly increased cocaine intake and cocaine-seeking behavior ( Fig. 2c and d) . The ANOVA conducted on the total number of cocaine infusions obtained revealed a significant effect of drug [F(4,24) = 3.83, P < 0.05]. The ANOVA conducted on the cumulative number of active lever presses per 10-min bin revealed a significant effect of time [F(23,552) = 191.77, P < 0.001] and a significant drug Â time interaction [F(92,552) = 2.16, P < 0.001]. Post-hoc LSD comparisons revealed that only rats receiving intra-ventral tegmental area SCH23390 obtained significantly more cocaine infusions (P < 0.05) and made significantly more active lever presses than saline-treated animals (P < 0.05). The ANOVA conducted on the total number of inactive lever presses revealed no significant effect. Four rats with guide cannula tips located outside the ventral tegmental area showed no change in cocaine self-administration following microinjection of terazosin (data not shown).
Discussion
In the current study, bilateral microinjections of the a1 noradrenergic antagonist, terazosin, into either the medial prefrontal cortex or ventral tegmental area failed to alter cocaine self-administration maintained under a fixed ratio 1 schedule at all doses tested. It is important to note that although a1 manipulation failed to produce even a trend in altering cocaine self-administration (Fig. 2) , bilateral microinjections of the D1 dopaminergic antagonist, SCH23390, into either the medial prefrontal cortex or ventral tegmental area significantly increased this behavior, consistent with previous reports [12, 13] . As always with negative findings, it is hard to conclude whether an effective dose of terazosin was used to alter self-administration; however, terazosin's lack of effect is consistent with previous studies demonstrating that systemic injection of another a1 selective antagonist, prazosin, fails to alter cocaine self-administration maintained under fixed ratio schedules [17, 18] . Similarly, cocaine self-administration is unaffected following systemic injection of broad-spectrum noradrenergic antagonists [4, 19] or lesions of the locus coeruleus [20] -the major source of noradrenergic input to the medial prefrontal cortex and ventral tegmental area. Therefore, unlike D1 dopaminergic signaling in the medial prefrontal cortex and ventral tegmental area [12, 13] , a1 receptor-mediated noradrenergic neurotransmission at these mesocortical sites does not appear to be critical for cocaine to maintain the steady rate of self-administration behavior that is characteristically observed in well-trained animals under fixed ratio schedules ( Fig. 2b and d) .
Noradrenergic signaling through a1 receptors has been suggested to contribute to cocaine self-administration under certain circumstances. Extended daily access to cocaine is known to lead to an escalated level of cocaine self-administration and is thought to model the excessive cocaine intake observed in addicts [21] . Systemic administration of prazosin (1.0 and 3.0 mg/kg, i.p.) effectively decreases escalated levels of responding for cocaine under a progressive ratio schedule in rats trained with 6-h daily access, whereas the same noradrenergic manipulation fails to alter the progressive ratio responding in rats trained with limited 1-h daily access to cocaine [21] . Therefore, it is possible that the current noradrenergic manipulation failed to alter cocaine self-administration because the rats were trained with 4-h, instead of 6-h, daily access. It is also possible that a1 signals in brain regions other than the medial prefrontal cortex or the ventral tegmental area may be important in cocaine selfadministration.
Although these possibilities need to be addressed in future research, the prazosin-induced reduction in the escalated level of cocaine self-administration [21] could reflect not only motivational but also motor deficits that are revealed only when lever-pressing requirements are greatly increased under the progressive ratio schedule. In this regard, a lower dose of prazosin (0.5 mg/kg, i.p.) than the doses effective at reducing the escalated levels of progressive ratio responding for cocaine [21] has been reported to reduce responding for food maintained under a fixed ratio 1 schedule [22] -a finding that is traditionally interpreted to reflect a performance deficit. Indeed, a predominant effect of a1 receptor antagonists, whether administered systemically or intracranially, is locomotor depression. For instance, systemic administration of prazosin decreases both cocaine-induced and amphetamine-induced hyperlocomotion [23] [24] [25] , and microinjection of prazosin into the medial prefrontal cortex [7, 8] decreases amphetamine-induced hyperlocomotion. Furthermore, microinjection of terazosin into the locus coeruleus depresses spontaneous locomotor activity in the home cage as well as the locomotor activating effects of a novel environment [26] . Mice lacking a1b receptors also exhibit reduced locomotor activation following a passive injection of cocaine or amphetamine [9, 10] . These data suggest that a1 receptor signaling may be involved in the locomotor activation, but not the self-administration, of cocaine.
Conclusion
Noradrenergic signaling through a1 receptors in the medial prefrontal cortex and ventral tegmental area does not appear critical for cocaine self-administration in welltrained animals. The maintenance of this behavior appears to be modulated by D1 dopaminergic, rather than a1 noradrenergic, signaling at these mesocorticolimbic sites.
